Assertio Therapeutics (ASRT) Misses Q1 EPS by 19c

Assertio Therapeutics (NASDAQ: ASRT) reported Q1 EPS of ($0.02), $0.19 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $15.6 million versus the consensus estimate of $37.51 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• After-Hours Stock Movers: FDX, CBRS, NKE
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance